Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

MR Guided Focused Ultrasound Surgery of Metastatic Bone Tumors

This study has been completed.
Information provided by (Responsible Party):
InSightec Identifier:
First received: July 6, 2006
Last updated: September 13, 2012
Last verified: September 2012
The objective of this trial is to evaluate the safety and effectiveness of MRgFUS in the treatment of metastatic bone tumors.

Condition Intervention Phase
Bone Metastases
Device: ExAblate 2000
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: MR Guided Focused Ultrasound Surgery of Metastatic Bone Tumors

Resource links provided by NLM:

Further study details as provided by InSightec:

Primary Outcome Measures:
  • Determine safety of MRgFUS of Bone Metastases [ Time Frame: Within 1 month of Treatment ]

Enrollment: 10
Study Start Date: May 2006
Study Completion Date: February 2010
Primary Completion Date: February 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: ExAblate MRgFUS Device: ExAblate 2000

Detailed Description:

Bone is the third most common organ involved by metastasic disease behind lung and liver. In breast cancer, bone is the second most common site of metastatic spread, and 90% of patients dying of breast cancer have bone metastasis. Breast and prostate cancer metastasize to bone most frequently, which reflects the high incidence of both these tumors, as well as their prolonged clinical courses.

Post cancer survival has increased with improvement in early detection and treatments. As a consequence, the number of patients developing metastatic bone disease during their lifetime has also increased. Patients with bone metastasis from breast cancer have an average 2-year survival from the time of presentation with their first bone lesion. In patients who die from breast, prostate, and lung cancer, autopsy studies have shown that up to 85% have evidence of bone metastases at the time of death.

Current treatments for patients with bone metastases are primarily palliative and include localized therapies (radiation and surgery), systemic therapies (chemotherapy, hormonal therapy, radiopharmaceutical, and bisphosphanates), and analgesics (opioids and non-steroidal anti-inflammatory drugs). Recently, radiofrequency ablation has been tested as a treatment option for bone metastases. The main goals of these treatments are improvement of quality of life and functional level. These goals can be further described: 1) Pain relief, 2) Preservation and restoration of function, 3) Local tumor control, 4) Skeletal stabilization.

The study hypothesis is that MRgFUS is a safe and potentially effective non-invasive treatment for metastatic bone tumors with a low incidence of co-morbidity. Based on the result of this study the Sponsor will initiate a larger study in an effort to approve metastatic bone tumors as an indication for its MRgFUS ExAblate device.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Men and women age 18 and older
  2. Patients who are able and willing to give consent and able to attend all study visits
  3. Patients with histologically or cytologically confirmed malignant disease with a bone lesion that appears to be metastatic disease by clinical and or imaging techniques
  4. Must have persistent pain from at least one site of bone metastases

    • Patient with VAS pain score ≥ 4, when VAS test taken without medication, OR
    • Patient taking pain-relieving medication for management of bone metastases.
  5. Targeted tumor(s) are ExAblate device accessible
  6. Targeted tumor(s) size is smaller than 8 cm in diameter
  7. Patient whose lesion is on bone and is ≥ 10-mm from the skin.
  8. Tumor(s) clearly visible by non-contrast MRI
  9. Able to communicate sensations during the MRgFUS ExAblate treatment
  10. At least 2 weeks since chemotherapy
  11. At least 1 month since radiation therapy

Exclusion Criteria:

  1. Diffuse skeletal tumoral spread as evaluated by imaging.
  2. Patients who need pre-treatment surgical stabilization of the affected bony structure.
  3. Targeted tumor is in weight bearing bones or impending fracture
  4. Targeted tumor is in the vertebral column.
  5. Patients with unstable cardiac status including:

    • Unstable angina pectoris on medication
    • Patients with documented myocardial infarction within six months of protocol entry
    • Congestive heart failure requiring medication (other than diuretic)
    • Patients on anti-arrhythmic drugs
  6. Severe hypertension (diastolic BP > 100 on medication)
  7. Patients with standard contraindications for MR imaging such as non-MRI compatible implanted metallic devices including cardiac pacemakers, size limitations (weight >250 pounds), etc.
  8. Known intolerance or allergies to the MRI contrast agent (e.g. Gadolinium or Magnevist)
  9. ASA Score>2 (See "Definitions" below)
  10. Extensive scarring in an area in the path of energy planned passage to the treatment area
  11. Severe cerebrovascular disease (multiple CVA or CVA within 6 months)
  12. Patients on anti-coagulation therapy or those with an underlying bleeding disorder.
  13. Individuals who are not able or willing to tolerate the required prolonged stationary position during treatment (approximately 3 hrs.)
  14. Patient whose lesion is < 10-mm from the skin
  15. Patients with < 2-Weeks since chemotherapy
  16. Patient with < 1-Month since radiation therapy
  17. Patients with life expectancy < 6-Months
  18. Patients with surgical stabilization of tumor site with metallic hardware
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00350233

United States, California
University of California at San Diego
LaJolla, California, United States, 92037
Canada, Ontario
Toronto General Hospital
Toronto, Ontario, Canada, MG5 2C4
Sponsors and Collaborators
Principal Investigator: Christine Chung, M.D. University of California, San Diego
Principal Investigator: David Gianfelice, M.D. Toronto General Hospital
  More Information

Additional Information:
Responsible Party: InSightec Identifier: NCT00350233     History of Changes
Other Study ID Numbers: BM002
Study First Received: July 6, 2006
Last Updated: September 13, 2012

Keywords provided by InSightec:
Bone Tumors
Bone Cancer
Prostate Cancer
lung cancer

Additional relevant MeSH terms:
Bone Neoplasms
Neoplasms by Site
Bone Diseases
Musculoskeletal Diseases processed this record on April 24, 2017